naabt masthead for buprenorphine site

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Attention: Research Survey Opportunity - Completed


If you have filled at least one prescription for a product that contains buprenorphine to treat opioid dependence in the past year, please consider taking this survey. The purpose of this survey is to understand your true feelings and concerns about your current treatment with buprenorphine:

The 10-12 minute survey can be taken online. Your responses to survey questions will be anonymous and will not change your treatment in any way.

To thank you for completing the survey, you can choose to be entered into a drawing to win the grand prize, a $500 gift card or a $50 gift card (there are 40 available). Instructions for obtaining a winning gift card will be provided when the survey is completed.

If you have questions about this survey, please email: jerichsen[at]

To take this survey now, please click here: Completed- Thank you.

Drawing winners have been notified.

*NAABT has thoroughly vetted this opportunity and can confirm it is a respectable organization.    Survey Privacy Policy

Why this survey matters

This page was last modified on : 08/08/2014

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release